Antifungal Agents

Correct Answer

A — Caspofungin

Rationale

Caspofungin is an echinocandin antifungal, the first agent of this class to receive approval. The echinocandins are cyclic lipopeptides that inhibit fungal cell wall synthesis and represent the third major class of antifungal agents alongside the polyenes and the azoles. Voriconazole is a second-generation extended-spectrum triazole that inhibits fungal cytochrome P450 51. Amphotericin B is a polyene antifungal that binds ergosterol in the fungal cell membrane. Terbinafine is an allylamine that inhibits squalene epoxidase in the ergosterol biosynthesis pathway.

Correct Answer

C — Cyclic lipopeptides that inhibit beta-1,3-d-glucan synthase in the fungal cell wall

Rationale

The echinocandins are classified as cyclic lipopeptides, a structural label that reflects their large ring peptide backbone with attached lipid side chains. Their pharmacological target is beta-1,3-d-glucan synthase, the enzyme complex encoded by the FKS1 and FKS2 genes that synthesizes beta-1,3-d-glucan, an essential structural polymer of the fungal cell wall. Macrolide polyenes binding ergosterol describes the polyene class, exemplified by amphotericin B and nystatin. Fluorinated pyrimidine antimetabolites inhibiting nucleic acid synthesis describes flucytosine. Triazole compounds coordinating with heme iron of cytochrome P450 51 describes the azole antifungals.

Correct Answer

A — Micafungin

Rationale

Micafungin is the only echinocandin with regulatory approval for use in pediatric patients as young as three months of age, for both treatment of invasive candidiasis and prophylaxis in hematopoietic stem cell transplant recipients. This approved age range — down to three months — distinguishes micafungin from caspofungin, which has a pediatric indication but with a lower age limit of three months only in some regions and is dosed by body weight. Anidulafungin does not have approved pediatric labeling in most jurisdictions for patients below two years of age. The three echinocandins are not interchangeable in their approved pediatric population labels; micafungin has the broadest and most established pediatric approval.

Correct Answer

D — Caspofungin

Rationale

Caspofungin was the first echinocandin to receive regulatory approval, approved in 2001 — an approval that established the echinocandin class as the third major category of antifungal agents alongside the polyenes and the azoles. Micafungin received approval in 2005 and anidulafungin in 2006. The sequential approvals reflect an active period of echinocandin drug development in the early 2000s, with each subsequent agent offering somewhat different pharmacokinetic profiles and approved indications. Caspofungin's first-in-class status is part of its categorical identity in antifungal pharmacology, and recognizing it as the prototype echinocandin is the same classification knowledge used to understand why it is the most thoroughly studied agent in the class.

Correct Answer

C — Intravenous administration only — no oral formulation is available for any echinocandin

Rationale

All three approved echinocandins — caspofungin, micafungin, and anidulafungin — are classified as intravenous-only agents. No oral formulation of any echinocandin is available for clinical use. This is a defining class characteristic: echinocandins are large cyclic lipopeptide molecules with poor oral bioavailability, and all clinical indications require intravenous administration. This distinguishes echinocandins sharply from azole antifungals such as fluconazole and voriconazole, which have oral formulations with high bioavailability that allow intravenous-to-oral step-down therapy. In clinical practice, the lack of an oral echinocandin means that step-down therapy from an echinocandin — after initial treatment of candidemia — typically transitions to oral fluconazole when the organism is susceptible, not to an oral echinocandin agent.

Correct Answer

B — Active against Candida species and Aspergillus species, but not against Cryptococcus neoformans or the Mucorales

Rationale

The echinocandin class is classified as active against Candida species — where it is fungicidal — and Aspergillus species — where it is fungistatic — but is inactive against Cryptococcus neoformans and the Mucorales. The absence of echinocandin activity against Cryptococcus reflects that organism's minimal cell wall beta-1,3-d-glucan content, which removes the drug target. The absence of activity against the Mucorales reflects a similar intrinsic target limitation. These spectrum gaps are defining categorical features of the echinocandin class and explain why echinocandin therapy alone cannot be used for cryptococcal meningitis or mucormycosis, and why patients receiving echinocandin prophylaxis remain at risk for these infections. The class is not narrow-spectrum by the azole standard — Aspergillus coverage is clinically meaningful — but it is clearly not broad-spectrum across all major fungal pathogens.

Correct Answer

C — Non-competitively inhibiting beta-1,3-d-glucan synthase at the Fks subunit, destabilizing the cell wall and leading to osmotic lysis

Rationale

Echinocandins are cyclic lipopeptides that act as non-competitive inhibitors of beta-1,3-d-glucan synthase, binding to the Fks subunit at the inner leaflet of the plasma membrane and blocking glucan chain elongation. Beta-1,3-d-glucan is an essential structural polymer providing tensile strength and maintaining cell shape and osmotic integrity. Its depletion destabilizes the cell wall and leads to osmotic lysis and rapid cell death — a concentration-dependent, fungicidal mechanism. Because mammalian cells lack a cell wall and do not synthesize beta-1,3-d-glucan, this target is exquisitely fungal-specific. Binding ergosterol to form transmembrane pores describes polyene antifungals such as amphotericin B. Inhibiting lanosterol 14-alpha-demethylase describes azole antifungals. Inhibiting squalene epoxidase describes allylamine antifungals such as terbinafine.

Correct Answer

B — The ratio of the area under the concentration-time curve to the minimum inhibitory concentration, indicating that total drug exposure over time drives the fungicidal effect

Rationale

Echinocandin fungicidal activity against Candida is driven by the area under the concentration-time curve to minimum inhibitory concentration ratio — an area-under-the-curve to minimum-inhibitory-concentration pharmacodynamic index. This means that total drug exposure over the dosing interval, rather than the time the concentration remains above a threshold or the peak concentration alone, is the primary determinant of effect. This relationship between total drug exposure and minimum inhibitory concentration supports once-daily dosing regimens that achieve adequate total daily exposure. Time above minimum inhibitory concentration is the pharmacodynamic index for beta-lactam antibiotics, where prolonged exposure is key. Peak to minimum inhibitory concentration ratio drives aminoglycoside and fluoroquinolone bactericidal activity. Trough-dependent activity describes a different pharmacodynamic pattern than the one that drives echinocandin fungicidal effect.

Correct Answer

D — Echinocandins penetrate poorly into the vitreous humor and central nervous system, making them inadequate for infections at these sites

Rationale

All three echinocandins share a class pharmacokinetic limitation: poor penetration into the central nervous system and vitreous humor of the eye. This distribution property makes them inadequate as sole therapy for Candida endophthalmitis or central nervous system candidiasis, which require alternative agents — typically fluconazole, which achieves excellent central nervous system and ocular penetration, or liposomal amphotericin B for severe disease. Echinocandins are fungicidal against Candida at all sites where drug concentrations are adequate; the issue is inadequate drug delivery to the vitreous, not altered activity at that site. Echinocandins are not inactivated by ocular enzymes. Although they are highly protein-bound — above 97 percent — large molecular size is the dominant pharmacokinetic constraint cited for poor ocular penetration rather than protein binding alone.

Correct Answer

A — Reduce the maintenance dose to 35 mg once daily while retaining the 70 mg loading dose on day one

Rationale

For patients with moderate hepatic impairment corresponding to a Child-Pugh score of 7 to 9, caspofungin maintenance dosing is reduced from 50 mg to 35 mg once daily. The 70 mg loading dose on day one is retained because it is needed to achieve therapeutic concentrations promptly — omitting the loading dose would delay adequate drug exposure by approximately two weeks given the long terminal half-life. The loading dose is not reduced. Non-enzymatic elimination independent of hepatic function describes anidulafungin, not caspofungin. Caspofungin is not absolutely contraindicated in hepatic impairment; dose reduction manages the increased exposure. Micafungin is a reasonable alternative in hepatically impaired patients, but this does not mean caspofungin is contraindicated.

Correct Answer

C — Anidulafungin undergoes slow non-enzymatic chemical degradation at physiological temperature and pH to an open-ring peptide product, with no hepatic or renal enzymatic involvement

Rationale

Anidulafungin is eliminated by slow spontaneous chemical degradation that occurs at physiological temperature and pH — a process driven by chemical conditions rather than by any enzymatic pathway. The degradation product is an open-ring peptide that is then excreted in bile. Because this elimination mechanism depends on chemistry rather than on hepatic enzymes, renal filtration, or cytochrome P450 activity, anidulafungin pharmacokinetics are unaffected by organ dysfunction of any degree. This makes it the echinocandin with the most straightforward dosing in patients with multiorgan dysfunction or complex polypharmacy. Anidulafungin is not renally excreted as unchanged drug, is not metabolized by erythrocytes, and is not secreted unchanged into bile — the parent drug degrades chemically before biliary excretion of its degradation product.

Correct Answer

B — All three echinocandins target the same Fks hot spot regions, so mutations reducing binding affinity for one agent reduce binding affinity for all three

Rationale

The primary mechanism of acquired echinocandin resistance is mutation in the hot spot regions of the FKS1 or FKS2 genes encoding the Fks glucan synthase subunit. Two hot spot regions have been characterized: hot spot 1 spanning amino acids 641 to 649 and hot spot 2 spanning amino acids 1345 to 1365. Mutations at specific positions within these hot spots — most commonly serine-to-leucine or serine-to-phenylalanine substitutions — reduce the binding affinity of the drug for the Fks enzyme. Because all three echinocandins bind to the same Fks hot spot regions, a mutation that reduces binding for micafungin also reduces binding for caspofungin and anidulafungin. Switching within the echinocandin class for FKS-mediated resistance is not effective; liposomal amphotericin B is the standard alternative. FKS mutations do not upregulate efflux pumps; they alter the binding target directly.

Correct Answer

D — Cryptococcus neoformans has minimal beta-1,3-d-glucan in its cell wall, removing the drug target that echinocandins depend on for activity

Rationale

Echinocandins lack activity against Cryptococcus neoformans because this organism has minimal beta-1,3-d-glucan in its cell wall. The echinocandin mechanism depends entirely on the presence of beta-1,3-d-glucan synthase activity and adequate glucan in the cell wall as a structural target; when the target is absent or minimal, the drugs have nothing to act on. This is an intrinsic, target-related limitation — not an acquired resistance mechanism, not a pharmacokinetic penetration problem, and not related to ergosterol. Cryptococcal meningitis induction requires a fungicidal polyene-based regimen — liposomal amphotericin B plus flucytosine — precisely because echinocandins and azoles alone are inadequate for this indication. Cryptococcus does use ergosterol, not cholesterol, in its membrane, which is why polyenes and azoles retain activity against it.

Correct Answer

A — Echinocandins, because Candida auris is typically susceptible while often resistant to azoles and variably susceptible to polyenes

Rationale

Echinocandins are the drug of choice for Candida auris infections pending susceptibility data. Candida auris is typically echinocandin-susceptible across most clinical isolates, while showing frequent resistance to fluconazole and other azoles, and variable susceptibility to amphotericin B with some clades carrying isolates above polyene susceptibility breakpoints. Susceptibility testing is mandatory for all Candida auris isolates because resistance patterns vary by clade and geographic origin. Fluconazole should not be used empirically for Candida auris because azole resistance is common in this species. Liposomal amphotericin B has variable activity against Candida auris and is not the empirical drug of choice. Voriconazole does not overcome the resistance mechanisms present in azole-resistant Candida auris isolates, which often involve pan-azole resistance mechanisms.

Correct Answer

D — Cryptococcus neoformans has minimal beta-1,3-d-glucan in its cell wall, so the drug target that echinocandins depend on for activity is essentially absent in this organism

Rationale

Echinocandins are ineffective against Cryptococcus neoformans not because of poor penetration or acquired resistance, but because the drug target is absent. Cryptococcus neoformans has minimal beta-1,3-d-glucan in its cell wall — the structural polymer that echinocandins inhibit synthesis of — so there is nothing for the drug to act on regardless of the concentration achieved. This is an intrinsic, target-related limitation that applies to all three echinocandins equally and cannot be overcome by dose escalation. The standard induction regimen for cryptococcal meningitis is liposomal amphotericin B combined with flucytosine, which provides rapidly fungicidal activity against this organism. The intern's reasoning — that fungicidal activity would be an advantage — is correct in principle but fails because the fundamental drug target is absent. Poor CNS penetration, while also a limitation of echinocandins at other sites, is not the primary explanation for echinocandin failure against Cryptococcus. Acquired FKS mutations are found in Candida species under echinocandin selection pressure, not as a natural feature of Cryptococcus.

Correct Answer

B — Co-administration of cyclosporine with caspofungin increases caspofungin exposure and is associated with liver enzyme elevations, which is particularly concerning in a liver transplant recipient

Rationale

Cyclosporine increases caspofungin area under the concentration-time curve by approximately 35 percent, and this combination is associated with transient liver enzyme elevations. While this interaction is clinically manageable in many patients, it is particularly undesirable in liver transplant recipients whose baseline hepatic function may already be compromised and who require careful monitoring of graft function. Micafungin and anidulafungin do not have this interaction with cyclosporine and are preferred in this population. Caspofungin is not a cytochrome P450 3A4 inhibitor and does not raise cyclosporine concentrations. The concern is a bidirectional pharmacokinetic interaction that raises caspofungin levels with hepatic consequences, not a reduction of caspofungin to subtherapeutic levels. Caspofungin does not induce P-glycoprotein to the degree that would reduce cyclosporine concentrations meaningfully.

Correct Answer

A — Transition to oral fluconazole, which inhibits fungal cytochrome P450 51 and provides fungistatic suppression adequate now that fungal burden has been substantially reduced

Rationale

This patient meets all criteria for step-down from echinocandin to oral fluconazole: clinical improvement with defervescence and hemodynamic stability, tolerating oral medications, blood cultures documented negative, species confirmed fluconazole-susceptible, and no evidence of deep-seated infection requiring prolonged intravenous therapy. Fluconazole inhibits fungal cytochrome P450 51, depleting ergosterol and providing fungistatic activity. While azoles are fungistatic rather than fungicidal, fungistatic suppression is adequate in the step-down phase because the echinocandin induction course has already achieved substantial fungal burden reduction. Total treatment duration for uncomplicated candidemia is 14 days from the first negative blood culture. Fixed-duration intravenous echinocandin courses regardless of clinical response are not standard practice. Voriconazole and itraconazole are not preferred step-down agents for uncomplicated Candida albicans candidemia when fluconazole susceptibility is confirmed.

Correct Answer

D — Rifampin induces drug transporters that reduce caspofungin trough concentrations by approximately 30 percent, requiring escalation of the maintenance dose to 70 mg once daily

Rationale

Rifampin is a potent inducer of drug transporters and certain metabolic enzymes. When co-administered with caspofungin, rifampin reduces caspofungin trough concentrations by approximately 30 percent through transporter induction. The recommended management is to increase the caspofungin maintenance dose from 50 mg to 70 mg once daily when rifampin or other strong inducers — including efavirenz, phenytoin, carbamazepine, and dexamethasone — are co-administered. The 70 mg loading dose on day one is unchanged. Caspofungin is administered intravenously and gastrointestinal absorption is not relevant. Isoniazid does not compete with caspofungin's N-acetylation pathway in a clinically meaningful way. Urinary acidification by pyrazinamide does not drive caspofungin clearance, as caspofungin is not renally eliminated.